Telix Pharmaceuticals Limited research snapshot
TLX AI stock analysis currently reads Telix Pharmaceuticals as a high-growth commercial-stage radiopharmaceutical company with FDA-approved Illuccix generating growing quarterly revenue, a deep pipeline of therapeutic candidates led by TLX591 in a Phase 3 prostate cancer trial, and expanding manufacturing and distribution capabilities globally. Telix reported fiscal year 2025 revenue of approximately $804 million USD, with Illuccix driving the commercial base, and a near-breakeven net income position of about -$7 million reflecting continued R&D investment. The ProstACT Global Phase 3 Part 1 data presented at ASCO 2026 showed encouraging safety and dosimetry, and the FDA recently aligned on the Part 2 protocol design. At the July 10, 2026 intraday reference of $11.14 and approximately 339 million shares outstanding (ADR equivalent basis), the verified market cap was about $5.5 billion. This TLX AI stock forecast is scenario-based, not a precise price prediction, and should be used as an informational research tool, not investment advice.
Current price
$11.14 intraday reference on July 10, 2026 (NASDAQ ADR)
Market cap
$5.52 billion market capitalization on July 10, 2026
AI score
67 / 100
Rating
Commercial-stage radiopharmaceutical company with growing Illuccix revenue, deep theranostics pipeline in prostate, kidney, and brain cancer, and Phase 3 therapy catalyst ahead
Trend status
Strong uptrend over the past 6 months (+55%) from the October 2025 lows, but pulled back from the $16.94 52-week high as the market digests pipeline timelines and dilution concerns
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Telix monetizes targeted radiation for cancer imaging and therapy through FDA-approved Illuccix and a pipeline of diagnostic and therapeutic radiopharmaceuticals. The theranostics model pairs diagnostic scans with targeted therapy, creating a sticky clinical workflow. | Medium-high |
| Moat | The moat comes from proprietary radiopharmaceutical manufacturing and supply chain expertise, FDA-approved product status, IP around antibody-chelator conjugates, and the operational complexity of radioligand theranostics. However, Novartis, Lantheus, and Eli Lilly are investing heavily in the same space. | Medium |
| Management | CEO Christian Behrenbruch has led Telix from a development-stage company to a commercial organization with global regulatory approvals and growing revenue. Capital allocation has prioritized R&D investment and global expansion, but the company has relied on equity and debt financing, creating dilution. | Medium |
| Financial trend | FY2025 TTM revenue reached approximately $804 million, with steady quarterly growth driven by Illuccix. Net income remains slightly negative at about -$7 million TTM as the company invests in R&D, manufacturing, and sales infrastructure across global markets. | High |
| Valuation | At $11.14, TLX screens at roughly 4.8x trailing revenue, 9.7x book value, and an enterprise value of about $4.3 billion or 5.4x revenue. The P/E is not meaningful due to near-zero EPS. Valuation relies on future revenue growth and margin expansion from the Illuccix franchise and pipeline. | Medium |
| Technical trend | The stock rallied from $6.28 in late 2025 to a 52-week high of $16.94, then corrected back to the $11-12 range. The 50-day moving average is being tested as support. Momentum has cooled but the longer-term uptrend from the October 2025 lows remains intact. | Medium |
| Risk level | Key risks are binary Phase 3 outcomes for TLX591, Illuccix revenue concentration, competitive pressure from Novartis and Lantheus, regulatory setbacks, equity dilution from ongoing capital needs, and foreign exchange risk given AUD reporting and global operations. | Medium-high |
| AI confidence | Descriptive data confidence is medium-high because Telix provides quarterly financials and ASX filings, but future pipeline revenue and probability-adjusted valuations depend on assumptions that cannot be verified from public data alone. | Medium-high data confidence |
| Investment certainty | TLX is an execution-dependent commercial-stage biotech with a strong Illuccix base, deep pipeline optionality, and significant upside potential if Phase 3 trials succeed, but investment certainty is reduced by binary catalysts, competitive intensity, and capital needs. | Medium-low |
TLX AI stock forecast
The TLX AI stock forecast uses the July 10, 2026 intraday reference of $11.14. Telix is near breakeven, so conventional P/E-based models are not meaningful. Instead, the scenarios are based on EV/revenue multiples and probability-weighted pipeline outcomes. These are scenario ranges, not promises.
$22 to $28
More likely if TLX591 Phase 3 succeeds, Illuccix continues its quarterly growth trajectory, pipeline candidates (TLX250, TLX101) show positive clinical data, the company reaches sustained profitability, and the market re-rates the stock toward 6-8x forward revenue.
$14 to $18
More likely if Illuccix maintains steady growth at current trajectory, TLX591 Phase 3 reads out with acceptable data, the pipeline advances without major setbacks, and the stock trades around 4-6x forward revenue, reflecting a typical commercial-stage biotech multiple.
$6 to $10
More likely if TLX591 Phase 3 or other key pipeline trials disappoint, Illuccix faces competitive pressure or reimbursement changes, equity dilution accelerates, the company needs more capital than expected, or the radiopharmaceutical sector falls out of favor.
TLX AI technical analysis
TLX technical analysis as of July 12, 2026 shows a stock that rallied sharply from its October 2025 lows near $6.28 to a 52-week high of $16.94, then corrected approximately 34% before finding support in the $11 area. The pullback has brought the stock below its 20-day moving average but it remains above the longer-term 50-day and 200-day moving averages, suggesting the primary uptrend is still intact but the short-term momentum has turned cautious.
| Level | Value | Why it matters |
|---|---|---|
| Resistance R1 | $13.20 | Recent swing high and the 20-day moving average area. A break above this level would signal the pullback may be over. |
| Resistance R2 | $14.85 | The 50-day moving average and a prior consolidation zone. This is the first major overhead resistance in a recovery scenario. |
| Resistance R3 | $16.94 | The 52-week high. A breakout above this level would indicate a resumption of the primary uptrend. |
| Support S1 | $10.70 | Near the July 2026 intraday low. This is the immediate support level that held during the recent pullback. |
| Support S2 | $9.50 | The 200-day moving average area. This would be a critical support level if the pullback deepens. |
| Support S3 | $6.28 | The 52-week low and the starting point of the recent rally. A break below this would invalidate the uptrend. |
| 50-day MA | ~$14.85 | The stock is currently trading below this level, which is a short-term caution signal. Reclaiming it would be bullish. |
| 200-day MA | ~$9.50 | The stock is above this level, indicating the longer-term trend remains positive. |
| RSI (14) | ~42 | RSI is in neutral territory but leaning toward oversold, suggesting the pullback may be maturing. |
TLX AI trading strategy
The TLX AI trading strategy framework adapts to Telix as a binary-event driven biotech stock. The approach combines trend structure for position sizing with event-aware risk management around Phase 3 data readouts and FDA decisions. This is a framework, not personalized advice.
Look for a base above the $10.70 support level with volume declining and the RSI stabilizing above 40. Enter on a break above $13.20 with increasing volume. Position size should account for the binary risk of trial outcomes.
Place a stop below $9.50 (200-day MA). Reduce position size by 50% if the stock cannot hold above $10.70 on a weekly closing basis.
If the stock pulls back to the $9.50-$10.00 zone on declining volume, consider a mean-reversion entry targeting a bounce back toward $12-13. This is a shorter-term setup suited for traders monitoring daily price action.
Stop at $8.90, below the 200-day MA. Take partial profits at $11.50 and $13.00. Do not hold this setup through binary events.
For TLX591 Phase 3 data, consider a smaller position sized to account for binary risk. If data is positive and the stock gaps up on volume, add on the first pullback that holds above the gap fill level.
Limit position size to 25-50% of normal due to binary risk. Define your invalidation level as the pre-event price. A gap-down below that level suggests the catalyst failed.
Investment research summary
Telix has built a commercial-stage radiopharmaceutical platform where diagnostic imaging agents identify cancer cells, then therapeutic candidates deliver targeted radiation. This Illuccix-to-TLX591 pipeline creates a clinical workflow that can lock in physician and patient adoption if the therapy candidate succeeds in Phase 3.
Telix owns or controls radiopharmaceutical manufacturing facilities in Australia, the US, and Belgium, with the supply chain expertise required for short-half-life radioisotopes. FDA and TGA approvals for Illuccix provide regulatory precedent. However, Novartis (Pluvicto) and Lantheus (Pylarify) have similar capabilities and deeper balance sheets.
TLX591 Phase 3 could miss efficacy or safety endpoints, leaving Telix as a single-product imaging company. Illuccix could face reimbursement cuts or competition. Telix may need dilutive capital raises to fund the pipeline. The radiopharma space could attract so much competition that margins compress. Management may overpay for acquisitions or expansion.
CEO Christian Behrenbruch, formerly of Siemens and GE Healthcare, has led Telix from development to commercial stage. Capital allocation has favored R&D breadth and global regulatory expansion, but the company has relied on equity and convertible debt. Insider ownership and share-based compensation should be monitored for alignment.
Radiopharmaceuticals represent a secular shift in oncology, combining the diagnostic precision of molecular imaging with targeted radiation therapy. Novartis Pluvicto has validated the model commercially. Telix is well positioned with a broad pipeline, but big pharma entrants (Eli Lilly, BMS) will intensify competition for indications, talent, and manufacturing isotopes.
At $11.14, TLX trades at about 4.8x TTM revenue and EV/Revenue of 5.4x, which prices in Illuccix growth but offers limited credit for pipeline success. If TLX591 succeeds, the stock could re-rate to 6-8x forward revenue. If it fails, Telix would need to rely solely on Illuccix imaging revenue, which would likely mean a lower multiple.
Watch quarterly Illuccix revenue growth rates, TLX591 Part 2 enrolment progress, cash burn and financing activity, competitive product approvals (Novartis, Lantheus), and any regulatory updates on pipeline candidates. The next major catalyst is the ProstACT Global Phase 3 data readout.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Stock price (NASDAQ ADR) | $11.14 (Jul 10, 2026 close) | Google Finance | July 12, 2026 |
| Market capitalization | $5.52 billion (Jul 10, 2026) | Google Finance | July 12, 2026 |
| Shares outstanding (ADR equivalent) | 339.38 million | Google Finance / Yahoo Finance | July 12, 2026 |
| TTM revenue (FY2025) | ~$804 million USD | Yahoo Finance / Google Finance | July 12, 2026 |
| TTM net income | ~ -$7 million USD | Yahoo Finance / Google Finance | July 12, 2026 |
| Cash and equivalents | $141.87 million (MRQ) | Yahoo Finance | July 12, 2026 |
| Enterprise value | ~$4.30 billion | Yahoo Finance | July 12, 2026 |
| 52-week price range | $6.28 - $16.94 | Google Finance / Yahoo Finance | July 12, 2026 |
| EV/Revenue (TTM) | ~5.4x | Yahoo Finance (calculated) | July 12, 2026 |
| Lead product | Illuccix (FDA-approved prostate cancer imaging) | Telix Pharmaceuticals | July 12, 2026 |
| Key pipeline candidate | TLX591 (Phase 3 ProstACT Global, prostate cancer therapy) | Telix Pharmaceuticals | July 12, 2026 |
| Employees | ~1,150 | Google Finance / Telix | July 12, 2026 |
This TLX AI stock analysis, forecast, technical analysis, and trading strategy are for informational and educational purposes only. They do not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any kind. All forecasts are scenario-based estimates using publicly available data as of July 12, 2026, and may be materially wrong. Past performance and AI-driven analysis do not guarantee future results. Investing in biopharmaceutical stocks, especially those with binary pipeline catalysts, involves significant risk of loss, including the potential loss of your entire investment. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
